Evidence map›Paper›PMID 30108613›Full record

ArticleJournal of geriatric cardiology : JGC2018

Influenza vaccination in acute coronary syndromes patients in Thailand: the cost-effectiveness analysis of the prevention for cardiovascular events and pneumonia.

Apirak Sribhutorn, Arintaya Phrommintikul, Wanwarang Wongcharoen, Usa Chaikledkaew, Suntara Eakanunkul, Apichard Sukonthasarn

Open access · greenAbstract read
In one paragraph

Article in Journal of geriatric cardiology : JGC, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 4 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Economic Burden of Influenza in Thailand: A Systematic Review.Inquiry : a journal of medical care organization, provision and financing
    Pooled it
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Apirak SribhutornProgram in Clinical Epidemiology, Faculty of Medicine, Chiang Mai University, Thailand.
Arintaya PhrommintikulCardiology Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Wanwarang WongcharoenCardiology Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Usa ChaikledkaewSocial and Administrative Pharmacy Excellence Research Unit (SAPER), Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Thailand.
Suntara EakanunkulDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Thailand.
Apichard SukonthasarnCardiology Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Chiang Mai University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfluenza vaccination has been clinically shown to reduce adverse cardiovascular outcomes in acute coronary syndrome (ACS) patients, but the economic perspectives can provide important data to make informed decisions. This study aimed to perform the economic evaluation of lifelong annual influenza vaccination for cardiovascular events and well-established pneumonia prevention.

methodsLifetime costs, life-expectancy, and quality-adjusted live years (QALYs) were estimated beyond one-year cycle length of a six-health states Markov model condition on whether a hospitalization for ACS, stroke, heart failure, pneumonia, no hospitalizations occurred, or death. The comparison of three age-groups of 40-49, 50-65, and > 65 years scenario was performed. Incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB) were presented as a societal perspective in 2016. The model robustness was determined by one-way and probabilistic sensitivity analyses.

resultsThe influenza vaccination was cost-effective in all age-groups, by dominant ICERs (lower cost with higher effectiveness) which was completely lower than acceptable willingness-to-pay threshold of Thailand [160,000 THB (4,466.8 USD) per QALYs], with a great incremental value of NMB. Especially, the 50-year-old-and-above scenario was shown as the most benefit at 129,092 THB (3,603.9 USD) for each patient.

conclusionsThe annually additional influenza vaccination to standard treatment in ACS was cost-effective in all age-groups, which should be considered in clinical practice and health-policy making process.

Indexed as

Acute coronary syndromeCost-effectivenessHeart failureInfluenza vaccinePneumoniaStroke

Identifiers

PMID30108613
PMCPMC6087522
OpenAlexW2910064244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.